Synergetic estrogen receptor-targeting liposome nanocarriers with anti-phagocytic properties for enhanced tumor theranostics
Synergetic estrogen receptor-targeting liposome nanocarriers with anti-phagocytic properties for enhanced tumor theranostics
复制标题
具有抗吞噬特性的协同雌激素受体靶向脂质体纳米载体，用于增强肿瘤治疗学
DOI：
10.1039/c8tb03351j
复制
发表时间：
2019
影响因子：
7
通讯作者：
Weizhi Wang
中科院分区：
文献类型：
--
作者：
Yuehua Wang;Zihua Wang;Yixia Qian;Linyang Fan;Chunyan Yue;Fei Jia;Jian Sun;Zhiyuan Hu;Weizhi Wang
多功能纳米载体因其对肿瘤的治疗作用而得到广泛应用。然而，由于生物体内的天然免疫清除机制，纳米载体往往在血液循环过程中被消除，从而阻碍它们有效到达肿瘤部位。在此，我们构建了一种协同靶向脂质体纳米载体系统，命名为SELS，其功能化有肿瘤识别配体（抗ER（雌激素受体）抗体）和免疫靶向配体（自身肽（SP））。抗ER抗体能特异性识别并结合ER阳性乳腺癌组织。SP可激活CD 47-SIRPα免疫应答，降低巨噬细胞对纳米粒的吞噬作用。增强的靶向能力和抗吞噬行为可以提高纳米载体的肿瘤摄取，并阻止其在生物系统中的免疫清除。因此，载药SELS能够改善活体系统中的肿瘤成像和治疗性能。
Multifunctional nanocarriers have been widely applied due to their enhanced effect on tumor therapeutics. Nevertheless, owing to the natural immune clearance mechanisms in living bodies, nanocarriers tend to be eliminated during blood circulation, thereby impeding their effective arrival at the tumor sites. Herein, we constructed a synergetic targeted liposome nanocarrier system named SELS functionalized with both a tumor identification ligand (anti-ER (Estrogen Receptor) antibody) and an immune targeting ligand (Self-Peptide (SP)). The anti-ER antibody could recognize and bind ER-positive breast cancer tissues in a specific way. SP could activate the CD47-SIRPα immune response, which reduced phagocytosis of the nanoparticles by macrophages. Both the enhanced targeting ability and anti-phagocytosis behavior could improve the tumor uptake of the nanocarriers and prevent their immune clearance in living systems. Therefore, drug-loaded SELS enabled improved tumor imaging and therapeutic performance in living systems.